Clinical Trial Update: Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor [Phase 2]

View source ↗

Summary

Phase 2 safety/tolerability study assessing Inebilizumab, VIB4920, or their combination in highly sensitized patients awaiting deceased-donor kidney transplanta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Inebilizumab (inebilizumab)
• VIB4920 (VIB4920)

Snippet

Sponsor: Amgen | Conditions: Highly Sensitized Patients on Waiting List for Kidney Transplantation | Phase 2 | Status: WITHDRAWN